HN21C0264

Hit and lead compound discovery of antibody-drug conjugate (ADC) targeting Doppel, a tumor-specific molecule

Seoul National University
서울대학교 SEOUL NATIONAL UNIVERSITY

ONCOLOGY | **Hit**

Product Type	Immunoglobulin product (mAb) (Antibody-Drug Conjugate)
Indication	Doppel-expressing cancer
Target	PRND (Doppel)
MoA(Mechanism of Action)	Binding to cell surface antigen → Internalization → Lysosomal degradation → Active payload release → Cell death → Amplification through bystander killing effect 
Competitiveness	First In Class • High efficacy & Low toxicity: Doppel is rarely expressed in normal tissues and specifically expressed only in tumor. • Overcome tumor heterogeneity: introducing new linker to induce bystander killing effect. • Patient selection: companion diagnostics using doppel as a biomarker
Development Stage	Hit
Route of Administration	Parenteral-Intravenous

kddf_bd@kddf.org
KDDF Business Development Team

KDDF Korea Drug Development Fund